StocksRunner logo
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  Highlights  
 
  Updates  
 
 
 
Ultragenyx Pharmaceu
53.31
-0.71%
 

RARE

 

Ultragenyx Pharmaceu

$ 53.31

 
-$0.38 | -0.71%
 
 
Open
$ 53.76
 
 
MKT CAP
$ 4.39B
 
High
$ 53.77
 
 
VOL
$ 0.00K
 
Low
$ 52.01
 
 
AVG VOL
$ 0.67M
 
 
 

RARE Stock Analysis

  Login to display Ultragenyx Pharmaceu (RARE) recommendation from the last 90 days from financial news and social media.
 
 

RARE Total Score

 
 

Strengths

RARE Rewards

 Upgraded on attractively valued

 
 

Chart

 
 

44.63

41.11

33.12

39.92

 
 
1month
3month
6month
1year
 
Total Return
RARE
vs.
S&P500
 

 
1-week Return
-0.65%
 
+1.04%
 
 
5-week Return
+18.55%
 
+4.91%
 
 
10-week Return
+10.58%
 
+7.60%
 
 
 

RARE Risk Level

This Indicator assigning RARE risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
RARE Risk Level
LOW
HIGH

Risk Volatility

 

RARE has Low Risk Level

Click here to check what is your level of risk

 

RARE Analysts Opinion

RARE overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information

 
 

Earnings

×
 

Earnings

3.20
 

RARE Earnings Sentiment

 Above analyst estimates

RARE Earnings Sentiment

 Reported a weak earnings

 
 

Rating

×
 

Rating

5.00
 

RARE Rating Sentiment

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

3.00
 
 

Activity

×
 

Activity

3.67
 
 

Future

×
 

Future

1.00
 
 
 

RARE Analysts Opinion

RARE Analysts opinion is negative but has improved from the past 3 months

 

RARE Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
71%
Buy
Opinion
Trend
Score
Potential
Score
 
 
100%
0%
0%
 
On Track
On Track
On Track
 

RARE Street Opinion 

RARE Street view is bullish but have mixed views on the near-term outlook

 

RARE Performance Sentiment

Sentiments overview associated with RARE events and the stock performance.
 
71%
29%
Positive
Negative
10 out of 14
events present
4 out of 14
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
 
Highlights
Last Modify
Price
% Change

 
HR Activity
1 Week Ago
49.48
+1.23%
 
Strong Earnings
2 Weeks Ago
46.26
+1.31%
 
Agreements
2 Weeks Ago
45.66
+3.82%
 
Weak Earnings
2 Weeks Ago
46.74
+0.02%
 
HR Activity
2 Month Ago
49.78
+4.58%
 
 
 
joker
 
 
 
StocksRunner

Explore our RARE Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored FDX Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our RARE Daily Alerts

Access the exclusive insights that over 10,000+ subscribers value. Stay ahead in the stock market! Submit your email for daily alerts.

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo

StocksRunner

Get the pulse of the market

 
StocksRunner
 
 
 
 

Stock Insights

 
 
 
 

Strengths

 

RARE Rewards

 Upgraded on attractively valued

 
 
 

RARE Risk Level

 
 
 

The Indicator assigning RARE risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
 
RARE Risk Level
LOW
HIGH

Risk Volatility

 

RARE has Low Risk Level. Click here to check what is your level of risk

 
 
 
 

Stock Analysis

 
 
 
 

RARE

 

Ultragenyx Pharmaceu

$ 53.31

 
-$0.38 | -0.71%
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  News  
 
  Updates  
 

 
joker
 
 
 
Open
$ 53.76
 
 
MKT CAP
$ 4.39B
 
High
$ 53.77
 
 
VOL
$ 0.00K
 
Low
$ 52.01
 
 
AVG VOL
$ 0.67M
 
 
 

RARE Analysis

  Sign in to view Ultragenyx Pharmaceu (RARE) recommendation from the last 90 days from financial news and social media.
 
 

Chart

 
 

44.63

41.11

33.12

39.92

 
 
1month
3month
6month
1year
 
Total Return
RARE
vs.
S&P500
 

 
1-week Return
-0.65%
 
+1.04%
 
 
5-week Return
+18.55%
 
+4.91%
 
 
10-week Return
+10.58%
 
+7.60%
 
 
 

RARE Analysts Opinion

RARE Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information

 
 

Earnings

×
 

Earnings

3.20
 

RARE Earnings Sentiment

 Above analyst estimates

RARE Earnings Sentiment

 Reported a weak earnings

 
 

Rating

×
 

Rating

5.00
 

RARE Rating Sentiment

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

3.00
 
 

Activity

×
 

Activity

3.67
 
 

Future

×
 

Future

1.00
 
 
 

RARE Analysts Opinion

RARE Analysts opinion is negative but has improved from the past 3 months

 

RARE Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
71%
Buy
Opinion
Trend
Score
Potential
Score
 
 
100%
0%
0%
 
On Track
On Track
On Track
 

RARE Street Opinion 

RARE Street view is bullish but have mixed views on the near-term outlook

 
RARE Performance Sentiment
Sentiments overview associated with RARE events and the stock performance.
 
71%
29%
Positive
Negative
10 out of 14
events present
4 out of 14
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Highlights
Last Modify
Price
% Change

 
HR Activity
1 Week Ago
49.48
+1.23%
 
Strong Earnings
2 Weeks Ago
46.26
+1.31%
 
Agreements
2 Weeks Ago
45.66
+3.82%
 
Weak Earnings
2 Weeks Ago
46.74
+0.02%
 
HR Activity
2 Month Ago
49.78
+4.58%
 
 
RARE Latest News Feed

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4). NOVATO Calif. Feb. 23 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) a biopharmaceutical company focused on the development and commercialization of novel

Fri Feb 23, 2024

Activity

Ultragenyx (RARE) Q4 Loss Narrower Than Expected Revenues Beat. Ultragenyx Pharmaceutical Inc.RARE incurred a loss of $1.52 per share in fourth-quarter 2023 narrower than the Zacks Consensus Es

Fri Feb 16, 2024

Earnings

Ultragenyx Pharmaceutical Inc Q4 Loss decreases beats estimates. (RTTNews) - Ultragenyx Pharmaceutical Inc (RARE) revealed Loss for fourth quarter that decreased from the same period last year and beat the Street estimates.

Thu Feb 15, 2024

Earnings

Ultragenyx (RARE) Reports Q4 Loss Tops Revenue Estimates. Ultragenyx (RARE) came out with a quarterly loss of $1.52 per share versus the Zacks Consensus Estimate of a loss of $1.65. This compar

Thu Feb 15, 2024

Earnings

Ultragenyx Pharmaceutical GAAP EPS of -$1.52 beats by $0.10 revenue of $127.39M beats by $5.34M.

Thu Feb 15, 2024

Earnings

Preview: Ultragenyx Pharmaceuticals Earnings. ) is set to give its latest quarterly earnings report on Thursday 2024-02-15. Here'.s what investors need to know before the announcement. Analysts estimate that Ultragenyx Pharmaceutical will report an

Wed Feb 14, 2024

Activity

What Analyst Projections for Key Metrics Reveal About Ultragenyx (RARE) Q4 Earnings. Analysts on Wall Street project that Ultragenyx (RARE) will announce quarterly loss of $1.65 per share in it

Mon Feb 12, 2024

Earnings

4 analysts have this to say about ultragenyx pharmaceutical. 4 analysts have shared their evaluations of ultragenyx pharmaceutical (nasdaq:) during the recent three months expressing a mix of ish and bearish perspectives. the table below summarizes their

Fri Jan 19, 2024

Potential

ultragenyxs (rare) preliminary 2023 revenues disappoint. ultragenyx pharmaceuticalrare reported preliminary total revenues (unaudited) of $430-$435 million for 2023 up 18-20% from 2022. the zac

Mon Jan 8, 2024

Activity
Activity

ultragenyx pharma gets positive recommendation from nice for evkeeza. (rttnews) - ultragenyx pharmaceutical inc. (rare) thursday announced that the national institute for health and care excellence (nice) has issued a final draft guidance recomm

Thu Jan 4, 2024

Rating

ultragenyx (rare) posts update from as study of gtx-102. ultragenyx pharmaceutical inc.rare completed enrollment in the new expansion cohorts in its early to mid-stage study of gtx-102 for the

Thu Jan 4, 2024

Activity

ultragenyx receives positive recommendation from nice in the United Kingdom for evkeeza® ▼ (evinacumab) for adolescents and adults aged 12 years and older with. novato calif. jan. 04 2024 (globe newswire) -- ultragenyx pharmaceutical inc. rare today annou

Thu Jan 4, 2024

Rating

 
 
 
 
 

Score Tracker

 
 
 
Based on 14 events in the last 90 days from financial news and social media. Last updated Mar 4, 2024 16:31 Wall St. time
 
 

RARE Total Score

 
 
 
 
 
 
 
StocksRunner

Discover RARE Stock analysis and effective trading strategies with StocksRunner. Gain valuable insights into stock performance, market trends, and the future potential of RARE. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our RARE Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

RARE Stock trends

RARE Stock performance

RARE Stock analysis

RARE investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
Post ×
 
0/666
joker